Sean Gerber Fundraising Page
Fundraising Header image
Sean Gerber Fundraising Page
Fundraising Page Image

GOAL 2019!!!

With funds raised from the AHC Foundation, we will support AAV gene therapy and other research related to the project.  We believe a path has been identified to a viable permanent treatment: gene therapy.  The gene therapy we propose will involve inserting a functional copy of the ATP1A3 gene into a virus (an adeno-associated virus or AAV) that has been stripped of its harmful payload and its ability to reproduce. The virus will then be injected into the cerebrospinal fluid and will carry the functional gene to the cells in the brain that are failing. By delivering additional functional copies of the gene, we should be able to rescue those cells, and treat the disease permanently. 

SEAN GERBER

Every year, AccountingDepartment.com donates a portion of its revenue to the Alternating Hemiplegia of Childhood Foundation(AHCF), an organization committed to funding desperately needed research. Alternating Hemiplegia of Childhood (AHC) is an extremely rare neurological disorder that affects less than 800 children in the entire world--of which one is the son of Bill Gerber, Co-Founder of AccountingDepartment.com.

Sean Gerber was diagnosed with AHC before his first birthday, after suffering mysterious and terrifying seizure-like symptoms and episodes that started appearing on just his second day of life. Now 16, Sean is a loving, sweet boy but still suffers from recurring episodes of paralysis, lasting days or weeks at a time.

Much research is needed to help advance the understanding of the causes and treatments for AHC--but unfortunately as it is such a rare disease, it gets little attention or support in larger philanthropy. AccountingDepartment.com is committed to raising awareness and funding to support AHCF and all the children and families living with AHC.

Every year we encourage our friends, families, clients and partners to consider giving a donation in Sean's name to AHCF.

ABOUT AAV Project and Other Research

With funds raised from the AHC Foundation, we will support AAV gene therapy and other research related to the project.  We believe a path has been identified to a viable permanent treatment: gene therapy.  The gene therapy we propose will involve inserting a functional copy of the ATP1A3 gene into a virus (an adeno-associated virus or AAV) that has been stripped of its harmful payload and its ability to reproduce. The virus will then be injected into the cerebrospinal fluid and will carry the functional gene to the cells in the brain that are failing. By delivering additional functional copies of the gene, we should be able to rescue those cells, and treat the disease permanently. 

Learn more about the project here. 

Supporters
Name Date Amount Comments
Southern Maine Senior Golfers' Association 08/05/2019 $250.00 Love you Sean
Joelle Mackey 05/17/2019 $.00  
Susan Fandacone 05/17/2019 $.00  
Joelle Mackey 05/17/2019 $100.00  
Linda Shropshire 04/26/2019 $25.00  
Raisa Usifer 04/26/2019 $50.00  
  Total $425.00  
Report Abuse Edit My Page